Abbott acquires CFR Pharmaceuticals.

An bout of typhoid fever, the primary end point for the trial, was a febrile episode in which S. Typhi was isolated from at least one bloodstream culture. An episode of paratyphoid fever, a second end stage for the trial, was a febrile episode in which S. Paratyphi was isolated from at least one blood culture but S. Typhi had not been isolated. The onset of an bout of typhoid or paratyphoid fever was considered to be the date of onset of fever that was reported through the first treatment check out for the show. Study Oversight The institutional review boards at the International Vaccine Institute, the National Institute of Cholera and Enteric Diseases, and the Indian Council of Medical Research approved the protocol and monitored the progress of the analysis.